Piramal Pharma promoters declare no share encumbrance in FY26

1 min read     Updated on 30 Jun 2026, 12:59 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Piramal Pharma Limited's promoters declared no encumbrance on shares for FY 2025-2026, complying with SEBI SAST regulations. The filing, signed by Ajay G. Piramal, confirms no direct or indirect pledge of securities.

powered bylight_fuzz_icon
44306929

*this image is generated using AI for illustrative purposes only.

Piramal Pharma Limited's promoters and promoter group have not encumbered any shares or securities of the company during the financial year 2025-2026. This disclosure ensures that the promoters have not pledged their holdings, providing clarity on the ownership structure to investors. The declaration was made in compliance with regulatory requirements to maintain transparency regarding promoter holdings.

The confirmation was submitted to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The regulation mandates such disclosures to inform the market about any potential changes in the ownership or control of the company's shares by its promoters.

Regulatory Filing Details

The filing was made on April 6, 2026, by Ajay G. Piramal on behalf of the promoter and promoter group. The document confirms that no direct or indirect encumbrance was created on the shares of piramal pharma during the specified financial year.

Parameter Details
Company Name Piramal Pharma Limited
BSE Script Code 543635
NSE Symbol PPLPHARMA
Regulation SEBI (SAST) Regulations, 2011
Financial Year 2025-2026
Filing Date April 6, 2026

Historical Stock Returns for Piramal Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+4.55%+4.93%+5.41%-1.42%-13.86%-5.17%

How will the unencumbered status of promoter holdings influence investor confidence and stock liquidity in the upcoming quarter?

Does Piramal Pharma plan to utilize its clean ownership structure to raise capital or pursue acquisitions in the near future?

How might this disclosure affect the company's credit rating and borrowing costs compared to industry peers with pledged shares?

Piramal Pharma schedules 6th AGM on July 30, 2026

1 min read     Updated on 20 Jun 2026, 05:55 AM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Piramal Pharma Limited has fixed July 30, 2026, as the date for its 6th Annual General Meeting, which will be held virtually via video conferencing. The company disclosed this information to exchanges under Regulation 30 of the SEBI Listing Regulations, following the publication of advertisements in Business Standard and Mumbai Lakshadweep. Shareholders will receive the AGM notice and Annual Report for FY 2025-26 electronically or via post, and those with shares in the escrow account must claim them to receive dividends.

powered bylight_fuzz_icon
43411703

*this image is generated using AI for illustrative purposes only.

Piramal Pharma Limited has scheduled its 6th Annual General Meeting (AGM) for July 30, 2026, at 3:00 p.m. IST through Video Conferencing and Other Audio Visual Means. The meeting will be conducted pursuant to the Ministry of Corporate Affairs General Circular No. 03/2025 dated September 22, 2025, and applicable SEBI regulations, permitting virtual meetings without physical presence.

The company informed the stock exchanges regarding the publication of newspaper advertisements to notify equity shareholders about the AGM. The intimation was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The advertisements were published in Business Standard (English) and Mumbai Lakshadweep (Marathi).

The Notice of the AGM along with the weblink for the Annual Report for FY 2025-26 will be sent electronically to members whose email addresses are registered with the company or depositories. Additionally, a letter containing the weblink and QR Code of the AGM notice will be sent to members who have not registered their email addresses, in compliance with Regulation 36(1)(b) of the SEBI Listing Regulations.

Attendance of members attending the AGM through VC/OAVM shall be counted for the purpose of reckoning quorum under Section 103 of the Companies Act, 2013. Members who have not registered their email addresses are encouraged to do so to receive the Notice and Annual Report. As per SEBI regulations, dividends can only be paid through electronic mode, and members must ensure their KYC and bank details are updated.

Members whose shares are lying in the Piramal Pharma Limited Escrow Account must claim their shares by submitting requisite documents to transfer them to their demat account before claiming unclaimed dividends. The filing was signed by Maneesh Sharma, Company Secretary & Compliance Officer of Piramal Pharma Limited.

Historical Stock Returns for Piramal Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+4.55%+4.93%+5.41%-1.42%-13.86%-5.17%

What key strategic initiatives or growth targets will management outline during the AGM for FY 2026-27?

How will the company address potential shareholder concerns regarding the continued reliance on virtual-only meetings?

What impact will the mandatory electronic dividend payment mandate have on shareholders with outdated bank details?

More News on Piramal Pharma

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-13.86%